$0.36
3.31% yesterday
Nasdaq, Nov 25, 10:16 pm CET
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Stock price

$0.36
-0.12 24.68% 1M
-0.60 62.57% 6M
-1.02 73.79% YTD
-3.48 90.58% 1Y
-10.40 96.64% 3Y
-48.09 99.25% 5Y
-26.81 98.67% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.01 3.31%
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

Key metrics

Market capitalization $70.33m
Enterprise Value $360.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.78
P/S ratio (TTM) P/S ratio 1.32
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 144.50%
Revenue (TTM) Revenue $53.12m
EBIT (operating result TTM) EBIT $-318.48m
Free Cash Flow (TTM) Free Cash Flow $-227.02m
Cash position $75.01m
EPS (TTM) EPS $-1.80
P/E forward negative
P/S forward 0.99
EV/Sales forward 5.05
Short interest 26.66%
Show more

Is bluebird bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a bluebird bio, Inc. forecast:

2x Buy
22%
6x Hold
67%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a bluebird bio, Inc. forecast:

Buy
22%
Hold
67%
Sell
11%

Financial data from bluebird bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
53 53
144% 144%
100%
- Direct Costs 86 86
244% 244%
163%
-33 -33
866% 866%
-63%
- Selling and Administrative Expenses 119 119
17% 17%
225%
- Research and Development Expense 110 110
39% 39%
206%
-262 -262
20% 20%
-494%
- Depreciation and Amortization 56 56
1,183% 1,183%
106%
EBIT (Operating Income) EBIT -318 -318
4% 4%
-600%
Net Profit -293 -293
221% 221%
-551%

In millions USD.

Don't miss a Thing! We will send you all news about bluebird bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

bluebird bio, Inc. Stock News

Positive
Seeking Alpha
6 days ago
Investment activity in October focused on Business Development Companies, with $1,300 added to the market. Adjusted dividend income in October of $789, up 25% Y/Y and up 11% sequentially. Main picks included Blackstone Secured Lending, Goldman Sachs BDC, and Midcap Financial Investment Corporation.
Negative
Proactive Investors
11 days ago
bluebird bio Inc (NASDAQ:BLUE) shares shed more than 11% on Friday after the Massachusetts-based biotech company developing gene therapies for severe genetic diseases was downgraded by Bank of America analysts. The analysts downgraded the company to ‘Neutral' and lowered their price target to $0.50 from $3 on their belief its key product launch, Lyfgenia for sick cell disease (SCD), will ramp s...
Neutral
Seeking Alpha
12 days ago
bluebird bio, Inc. (NASDAQ:BLUE ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director, Investor Relations Andrew Obenshain - Chief Executive Officer Tom Klima - Chief Commercial & Operating Officer James Sterling - Chief Financial Officer Conference Call Participants Jack Allen - Baird Gena Wang - Barclays Jason Gerberry - Bank of Ameri...
More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Obenshain
Employees 375
Founded 1992
Website www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today